Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism

amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L

Cardiovascular Diseases

cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound

cardiovascular screening

University Medical Center Utrecht

Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile

ultrasound measurement of thickness of carotid wall (mean IMT), presence of atherosclerotic plaques (yes/no, location)

serum measurement of low density lipoprotein cholesterol, triglycerides, total cholesterol, high density lipoprotein cholesterol

documentation of heart rythm, potential signs of ischemia (ST segment), length PR, QRS, QT, RR interval

measurement of left ventricular ejection fraction and left ventricular mass,

Bart CJM Fauser

professor

UMC Utrecht

VU University Medical Center

Erasmus Medical Center

Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Control

PCOS

Total

Sex: Female, Male

Region of Enrollment

Using serum total testosterone to represent the severity of hyperandrogenism.

Total Testosterone

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

A fasting serum insulin level of greater than the upper limit of normal for the assay used (approximately 60 pmol/L) is considered evidence of insulin resistance.

Fasting Insulin

Fasting blood sugar (FBS) measures blood glucose after you have not eaten for at least 8 hours. It is often the first test done to check for prediabetes and diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

Fasting Glucose

2-hour postprandial blood sugar measures blood glucose exactly 2 hours after you start eating a meal. This is not a test used to diagnose diabetes.
World Health Organization 2006 diagnostic criteria for diabetes were employed (fasting plasma glucose ≥7.0 mmol/L or two hour plasma glucose ≥11.1 mmol/L).

Two Hour Glucose

HOMA-IR = [fasting insulin (in μIU/mL) × fasting glucose (in mg/dL)]/405.

Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)

Hypercholesterolemia was defined as >6 mmol / L.

Cholesterol

Abnormal serum triglycerides defined as ≥ 1.7 mmol/L

Triglycerides

Metabolic syndrome was defined (2005 National Cholesterol Education Program, Adult Treatment Panel III) as the presence of at least three of the following criteria:
abdominal obesity (waist circumference >80 cm in women); serumtriglycerides≥1.7 mmol/L; serumHDL<1.3 mmol/L; systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg; and fasting plasma glucose ≥7.0 mmol/L.

Lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and sex hormone binding globulin (SHBG).
Abnormal LDL was ≧4.14mmol/L.

Impaired glucose tolerance was defined as two hour glucose levels of 7.8-11.1 mmol/L in the 75 g oral glucose tolerance test. In women with impaired glucose tolerance, the fasting plasma glucose level should be <7 mmol/L.

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI ≧ 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).
Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Obese With PCOS

Obese With Control

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI < 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).
Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
Oligo- or anovulation
Clinical and/or biochemical signs of hyperandrogenism
Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Non-obese With PCOS

BMI categorization was based on the WHO Asia-Pacific classification for obesity, which was defined as BMI < 25 kg/m2(WHO: Obesity: preventing and managing the global epidemic. Geneva: WHO; 2000).

primary ovarian insufficiency/adipositas

Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile

To Study Polycystic Ovary Syndrome in Taiwanese Women

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird